<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9214969</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2488</journal-id>
<journal-id journal-id-type="nlm-ta">Methods Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Methods Mol. Biol.</journal-id>
<journal-title-group>
<journal-title>Methods in molecular biology (Clifton, N.J.)</journal-title>
</journal-title-group>
<issn pub-type="ppub">1064-3745</issn>
<issn pub-type="epub">1940-6029</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31273690</article-id>
<article-id pub-id-type="pmc">6895673</article-id>
<article-id pub-id-type="doi">10.1007/978-1-4939-9554-7_1</article-id>
<article-id pub-id-type="manuscript">NIHMS1061328</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kaffman</surname>
<given-names>Arie</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>Jordon D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Lan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Johnson</surname>
<given-names>Frances K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krystal</surname>
<given-names>John H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1.</label>Department of Psychiatry, Yale University School of Medicine, New Haven, USA</aff>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>2011</volume>
<fpage>3</fpage>
<lpage>22</lpage>
<!--elocation-id from pubmed: 10.1007/978-1-4939-9554-7_1-->
<abstract id="ABS1">
<p id="P1">Most large pharmaceutical companies have downscaled or closed their clinical neuroscience research programs in response to the low clinical success rate for drugs that showed tremendous promise in animal experiments intended to model psychiatric pathophysiology. These failures have raised serious concerns about the role of preclinical research in the identification and evaluation of new pharmacotherapies for psychiatry. In the absence of a comprehensive understanding of the neurobiology of psychiatric disorders, the task of developing “animal models” seems elusive. The purpose of this review is to highlight emerging strategies to enhance the utility of preclinical research in the drug development process. We address this issue by reviewing how advances in neuroscience, coupled with new conceptual approaches, have recently revolutionized the way we can diagnose and treat common psychiatric conditions. We discuss the implications of these new tools for modeling psychiatric conditions in animals and advocate for the use of systematic reviews of preclinical work as a prerequisite for conducting psychiatric clinical trials. We believe that work in animals is essential for elucidating human psychopathology and that improving the predictive validity of animal models is necessary for developing more effective interventions for mental illness.</p>
</abstract>
<kwd-group>
<kwd>Animal models</kwd>
<kwd>Predictive validity</kwd>
<kwd>Psychiatry</kwd>
<kwd>Systematic reviews</kwd>
<kwd>CRF</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>